Effects of Interferon β1-a Administration in the First Versus Second Week of Treatment on Recovery in Patients with COVID-19: A Retrospective Study

HamidReza Samimagham1, Mehdi Hassani Azad2, Mohsen Arabi3, Sara Ghazizadeh4, Alireza Malektojjari4, Golbahar Ghasemi4 and Mitra Kazemi Jahromi5,*

1Clinical Research Development Center, Shahid Mohammadi Hospital, Hormozgan University of Medical Sciences, Bandar Abbas, Iran
2Infectious and Tropical Diseases Research Center, Hormozgan Health Institute, Hormozgan University of Medical Sciences, Bandar Abbas, Iran
3Preventive Medicine and Public Health Research Center, Family Medicine Department, Iran University of Medical Sciences, Tehran, Iran
4Student Research Committee, Faculty of Medicine, Hormozgan University of Medical Sciences, Bandar Abbas, Iran
5Endocrinology and Metabolism Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran

*Corresponding author: Endocrinology and Metabolism Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran Email: mitra.kazemijahromi@gmail.com

Received 2021 September 10; Revised 2022 February 19; Accepted 2022 February 28.

1. Background

A disease called COVID-19 broke out in Wuhan, China, in December 2019 and rapidly spread to other parts of China and the whole world. On February 12, 2020, the World Health Organization (WHO) officially coined the term COVID-19 for the disease caused by the novel coronavirus (1).

Due to its high prevalence, complications, and mortality rate (2), COVID-19 and its control and treatment methods have received increasing attention throughout the world. The entry receptor for COVID-19, called angiotensin-converting enzyme 2 (ACE2) receptor, is found in many different tissues, including the lungs, the heart, and the liver, making the virus extremely harmful (3). Since some viruses, e.g., coronavirus, poorly stimulate interferon synthesis, the body's natural defense mechanism against such infections is poorly activated. Based on the results of in vitro and in vivo experiments, interferon can strongly prevent cell proliferation, and therefore, interferon therapy is an alternative recommended for infections with coronaviruses (4). Given the effects of interferon on cells
(interferon-alpha on all cells and interferon-gamma on epithelial and certain immune cells), its early administration can efficiently inhibit the spread of SARS-CoV-2 virus (5). The delayed increase in interferon level in SARS-CoV-2 infection strongly activates macrophages (5). Postmortem examination revealed extremely high levels of pro-inflammatory macrophages in those who died of COVID-19 (6).

Type I interferons (IFN-α, IFN-β, IFN-ε, IFN-κ, IFN-ω in humans) bind to the type I interferon receptor (IFNAR) in an autocrine and paracrine manner. These receptors are found everywhere in the body. This pathway activates a powerful antiviral defense program of hundreds of interferon-stimulated genes (ISGs), which have the capacity to interfere with every step of viral replication (7).

Interestingly, although rapid production of interferon at the onset of the disease is an important factor for increasing T cells, increased interferon in later stages inhibits T cells or deplete their lymphoid tissues. Given the role of T cells in regulating the immune system function and the severe lung damage caused by cytokine release syndrome (CRS) in patients critically ill with COVID-19, the immune suppression dysfunction appears possible at this stage (6).

Hence, the timing of interferon administration in patients with COVID-19 appears important for the regulation of both macrophage function and lymphocyte function. Since the role of interferon administration timing has not been fully investigated, we designed a retrospective study on hospitalized patients with COVID-19 to illuminate the subject.

2. Methods

The present single-center retrospective cohort study was conducted using the data extracted from the hospital information system (HIS) and archived patient records. The study protocol was approved by the Ethics Committee of Hormozgan University of Medical Sciences, Iran (code: IR.HUMS.REC.1399.479).

2.1. Participants

The present study was conducted in Bandar Abbas (a city in Iran). A total of 200 patients admitted to Shahid Mohammadi Hospital were enrolled. All eligible patients who aged 18 - 90 years entered the study from early 2020. They all underwent the treatment regimen approved by the WHO for patients with moderate COVID-19. Demographic data are shown in Table 1, baseline data were similar in the two groups. The participants were divided into two equal groups. In addition to the routine care, the first group (IFNw1) received IFNβ1-a in the first week of treatment and the second group (IFNw2) received IFNβ1-a in the second week of treatment. The medication used for these patients was interferon β1-a (ReciGen®) administered in 44 µg doses (total 12 million units). It was administered every other day for five days.

| Variables                        | IFNw1 (n = 100) | IFNw2 (n = 100) | P-value *
|---------------------------------|----------------|----------------|----------------
| Age (mean ± SD)                 | 50.00 ± 15.03  | 52.01 ± 13.0    | 0.12           |
| Female (%)                      | 42.03          | 38.02          | 0.17           |
| Diabetes mellitus (%)           | 12.01          | 14.01          | 0.28           |
| Hypertension (%)                | 24.02          | 22.03          | 0.42           |
| Ischemic heart disease (%)      | 92.00          | 9.00           | 0.48           |

* P-value > 0.05 was considered significant.

2.2. Inclusion Criteria

Routine pharmacotherapy according to the National Committee of COVID-19 treatment protocols included: (1) hydroxychloroquine/chloroquine phosphate: hydroxychloroquine sulfate tablets 200 mg or chloroquine phosphate tablets 250 mg (equivalent to 150 mg base amount); (2) Kaletra tablets (lopinavir/ritonavir) 200/50 mg; (3) Atazanavir/Ritonavir 300/100 tablet: one tablet a day with food; or Atazanavir 400 mg daily for a minimum of seven days and a maximum of 14 days.

All patients were followed-up until discharge, and the mortality rate and laboratory data over this period were extracted from the HIS. Patients visiting the Center for Acute Respiratory Diseases of Shahid Mohammadi Hospital were screened for COVID-19 and enrolled if COVID-19 was confirmed based on clinical signs, a positive PCR test, and spiral chest CT-scan.

2.3. Exclusion Criteria

The exclusion criteria were as follows: (1) cardiovascular diseases: History of recent myocardial infarction, unstable angina, and history of QT prolongation on electrocardiogram (ECG); (2) end-stage renal disease; (3) history of glucose-6-phosphate dehydrogenase deficiency; (4) an alanine aminotransferase (ALT) to aspartate aminotransferase (AST) ratio greater than five times the upper limit of normal; (5) history of malignancy; (6) immune deficiency;
(7) absolute neutrophil count (ANC) < 2000; (8) systolic blood pressure > 160 mmHg; (9) diastolic blood pressure > 90 mmHg; (10) pregnancy; (11) primary and secondary objectives.

The primary objective of this study was to compare the effectiveness of IFN-β1-a administration in the first and second weeks of treatment on patient mortality. The secondary objective was to investigate the difference between IFN week 1 and IFN week 2 groups in terms of white blood cell (WBC), hemoglobin (Hb), urea, lactate dehydrogenase (LDH), and C-reactive protein (CRP) levels and length of hospitalization.

2.4. Statistical Methods

Data were analyzed using IBM SPSS 26 (SPSS Inc., Chicago, IL, USA). Frequency and Crosstab commands were applied to assess the frequency of qualitative data. Chi-square and Fisher’s exact tests were conducted to examine the relationship between two categorical variables. Independent sample t-test was used to compare the mean of two independent groups. The results were reported in binary form. P-values less than 0.05 were considered significant. Kolmogorov-Smirnov test was used to examine the normal distribution of data.

3. Results

A total of 200 patients admitted to COVID-19 wards of Shahid Mohammadi Hospital, Bandar Abbas, Iran were assessed. These patients had been admitted from May 1, 2020 to August 11, 2020. Their mean age was 52.00 ± 14.00 years (range: 25 - 90 years). Sixty patients (60.00%) were male, and 40 (40.00%) were female. Regarding underlying diseases, 22 patients (22.00%) reported a history of diabetes mellitus, 22 (22.00%) had a history of hypertension, one (1.00%) had a history of chronic renal failure, and 9.00% had a history of chronic heart disease (Table 1). A total of 31 patients died during hospitalization, and the rest were discharged (Table 1).

Patients were divided into two groups of 100 depending on whether they received IFN-β1-a in the first week or the second week of the onset of COVID-19 symptoms. The two groups had no significant differences in terms of age (P = 0.12) or sex (P = 0.17). Overall, 58 patients in the IFNw1 group (58.00%) and 62 patients in the IFNw2 group (62.00%) were male (Table 1). No significant difference was observed between the two groups in terms of baseline data (Table 1). All patients had a moderate COVID-19. Laboratory results pertain to the day of discharge.

The mortality rate and length of hospitalization were significantly lower in the IFNw1 group than in the IFNw2 group (P = 0.01 and P = 0.02, respectively). The mean CRP was significantly lower in the IFNw1 group than in the IFNw2 group (P = 0.02). The two groups had no significant differences in other laboratory findings at discharge (Table 2).

4. Discussion

The present retrospective study was conducted in Shahid Mohammadi Hospital (Bandar Abbas, Iran) with the aim to investigate the effects of timing of interferon β1-a administration on the treatment response of adult inpatients with moderate COVID-19. Thus, the relationship between the patients’ treatment process and the administration of IFN/β1-a in the first or second week of treatment was assessed. To this end, laboratory markers such as LDH, CRP, and WBC, as well as mortality rate, were assessed in both groups (Table 2). The results of statistical analysis showed a significantly lower mortality rate in the group that received interferon in the first week of treatment compared to the group that received interferon in the second week (13% vs. 18%; P-value = 0.01). Among laboratory markers, CRP was significantly lower in the IFNw1 group than in the IFNw2 group (15.04 ± 12.01 vs. 24.01 ± 16.03; P-value = 0.021). However, no significant difference was found between the two groups in other laboratory markers and length of hospitalization.

During the COVID-19 pandemic, the effects of IFN/β1-a, especially its administration time, were less evaluated compared to other medications. Meanwhile, in most cases, our findings appear to be in line with previous studies on this subject, confirming the relationship between the timing of IFN/β1-a administration and patient recovery. A retrospective study reported a lower mortality rate in patients who received interferon β1-a earlier. It also showed earlier hospital discharge in the interferon group than in other groups (8). Another study assessed the effects of ribavirin and interferon and reported significantly lower mortality rates with the administration of these medications. A clinical trial on interferon showed that it could reduce the length of hospitalization and, to some extent, mortality rate in patients (7). In this study, data for CT-Scan were not complete for all the population. So we could not use these data. Laboratory studies indicated a significant decline in the level of T cells, especially T-helper cells, which was even higher in critically ill patients (9). This effect can be justified by the role of interferon in T cell recovery.

Moreover, another study on laboratory markers showed that early administration of type I interferon protected patients with MERS-COV, while its late administration increased mortality due to the high activation of neu-
trophils and the elevated secretion of pro-inflammatory cytokines (10).

A study argued that interferon might induce ACE2, which is the SARS-CoV-2 receptor. This hypothesis was rejected by later research, and it was found that interferon does not promote the virus entry into the cells (11). In contrast, nonsteroidal anti-inflammatory drugs (NSAIDs) were found effective in this regard (12).

According to previous research, lymphocytes, especially T lymphocytes, have a major role in viral infections. A study conducted on mice in China showed that CD8$^+$ T lymphocytes had a central role in clearing the virus and dealing with the eosinophilic immunopathology in mice with SARS-CoV (7). Improper response of T lymphocytes can be due to the lack of interferon at the onset of the disease caused by the antagonistic function of the virus on this molecule (6). Our findings and the results of previous studies complement and support one another.

The limitations of this study included failure to control disease symptoms and failure to perform allocation concealment and randomization due to the retrospective nature of the study. The study population was statistically proportionate. Given the urgent need for information and evidence of the medication effects during the COVID-19 pandemic, the present study was conducted retrospectively. However, further studies and accurate clinical trials are required to confirm the obtained results.

### 4.1. Conclusion

There is a relationship between the timing of IFNβ-1a administration and the trend of recovery in patients with moderate COVID-19. Administration of interferon β-1a in the first days of treatment would reduce the inflammatory factors and mortality rates in these patients.

### Footnotes

#### Authors’ Contribution:
HR.S and M.KJ contributed to conception, design, and statistical analysis. Other authors contributed to data collection and manuscript drafting. M.KJ supervised the study. All authors approved the final version of the manuscript.

#### Conflict of Interests:
The authors declared that they have no conflict of interest.

#### Data Reproducibility:
The data presented in this study are uploaded during submission as a supplementary file and are openly available for readers upon request.

#### Ethical Approval:
The study protocol was approved by the Ethics Committee of Hormozgan University of Medical Sciences, Iran (code: IR.HUMS.REC.1399.479). ([ethics.research.ac.ir/EthicsProposalView.php?id = 172407](http://ethics.research.ac.ir/EthicsProposalView.php?id = 172407)).

#### Funding/Support:
Clinical Research Development Center of Shahid Mohammadi Hospital, Hormozgan University of medical sciences, Bandar Abbas, Iran.

#### Informed Consent:
Written informed consent was obtained.

### References

1. Zu ZY, Jiang MD, Xu PP, Chen W, Ni QQ, Lu GM, et al. Coronavirus Disease 2019 (COVID-19): A Perspective from China. *Radiology*. 2020;296(2):E5–25. doi: 10.1148/radiol.2020200490. [PubMed: 32083985]. [PubMed Central: PMC7213368].

2. Guarnotta V, Ferrigno R, Martino M, Barbot M, Isidori AM, Scaroni C, et al. Glucocorticoid excess and COVID-19 disease. *Rev Endocr Metab Disord*. 2021;22(4):703–14. doi: 10.1007/s11154-020-09598-x. [PubMed: 33025384]. [PubMed Central: PMC7538187].

3. Arabi M, Samimagham HR, Hooshayr D, Shariati Nabavi SJ, Kazemi-Jahromi M. The Association of Liver Enzymes with Disease Severity in PCR positive COVID-19 Patients. *Diabetes Obes Int J*. 2021;6(3):245.

4. Brzoska J, von Eick H, Hundgen M. Interferons in the Therapy of Severe Coronavirus Infections: A Critical Analysis and Recollection of a Forgotten Therapeutic Regimen with Interferon Beta.
5. Prokunina-Olsson L, Alphonse N, Dickenson RE, Durbin JE, Glenn JS, Hartmann R, et al. COVID-19 and emerging viral infections: The case for interferon lambda. J Exp Med. 2020;217(5). doi: 10.1084/jem.20200653. [PubMed: 32289152]. [PubMed Central: PMC7155807].

6. Acharya D, Liu G, Gack MU. Dysregulation of type I interferon responses in COVID-19. Nat Rev Immunol. 2020;20(7):397-8. doi: 10.1038/s41577-020-0346-x. [PubMed: 32457522]. [PubMed Central: PMC7249038].

7. Schoggins JW, Rice CM. Interferon-stimulated genes and their antiviral effector functions. Curr Opin Virol. 2011;1(6):519–25. doi: 10.1016/j.coovi.2011.10.008. [PubMed: 22328912]. [PubMed Central: PMC3274382].

8. Wang N, Zhan Y, Zhu L, Hou Z, Liu F, Song P, et al. Retrospective Multicenter Cohort Study Shows Early Interferon Therapy Is Associated with Favorable Clinical Responses in COVID-19 Patients. Cell Host Microbe. 2020;28(3):455–464 e2. doi: 10.1016/j.chom.2020.07.005. [PubMed: 32707096]. [PubMed Central: PMC7368556].

9. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis. 2020;71(15):762-8. doi: 10.1093/cid/ciaa248. [PubMed: 32160940]. [PubMed Central: PMC7108125].

10. Channappanavar R, Fehr AR, Zheng J, Wohlford-Lenane C, Abrahante JE, Mack M, et al. IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes. J Clin Invest. 2019;129(9):3625-39. doi: 10.1172/JCI126363. [PubMed: 31355779]. [PubMed Central: PMC6715373].

11. Onabajo OO, Banday AR, Yan W, Obajemu A, Stanifer ML, Santer DM, et al. Interferons and viruses induce a novel primate-specific isoform dACE2 and not the SARS-CoV-2 receptor ACE2. bioRxiv. 2020;Preprint. doi: 10.1101/2020.07.19.210955. [PubMed: 32743577]. [PubMed Central: PMC7386494].

12. Samimagham HR, Arabi M, Hooshyar D, Kazemjahromi M. The Association of Non-Steroidal Anti-Inflammatory Drugs with COVID-19 Severity and Mortality. Arch Clin Infect Dis. 2020;15(4). e106847. doi: 10.5812/archcid.106847.